Drug Information

Drug (ID: DG01060) and It's Reported Resistant Information

• Name: Cefsulodin
• Synonyms: Cefsulodin; Cefsulodine; Cefsulodinum; Cefsulodino; 62587-73-9; UNII-OV42LHE42B; OV42LHE42B; (6R,7R)-3-[(4-carbamoylpyridin-1-ium-1-yl)methyl]-8-oxo-7-[[(2R)-2-phenyl-2-sulfoacetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; CHEBI:3507; (6R,7R)-3-[(4-carbamoylpyridinium-1-yl)methyl]-8-oxo-7-{[(2R)-2-phenyl-2-sulfoacetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; 7beta-{[(2R)-2-phenyl-2-sulfoacetyl]amino}-3-(4-carbamoylpyridinium-1-yl)methyl-3,4-didehydrocepham-4-carboxylate; Cefsulodin [INN:BAN]; Cefsulodine [INN-French]; Cefsulodinum [INN-Latin]; Cefsulodino [INN-Spanish]; Cefonomil; Cefsulodin (INN); Epitope ID:120379; SCHEMBL65525; CGP7174/E; GTPL10783; CGP-7174-E; DB13499; (6R,7R)-3-((4-carbamoylpyridinio)methyl)-8-oxo-7-((R)-2-phenyl-2-sulfoacetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carboxylat; 4-Carbamoyl-1-(((6R,7R)-2-carboxy-8-oxo-7-((2R)-2-phenyl-2-sulfoacetaido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)pyridinium hydroxide, inner salt; D07653; Pyridinium, 4-(aminocarbonyl)-1-((2-carboxy-8-oxo-7-((phenylsulfoacetyl)amino)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, (6R-(6alpha,7beta(R*)))-
• Indication:
  In total 1 Indication(s)
  Pseudomonas infection [ICD-11: 1B92]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Bacterial infection [ICD-11: 1A00-1C4Z]; [1]
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Bacterial infection [ICD-11: 1A00-1C4Z]; [2]
• Formula: C22H20N4O8S2
• IsoSMILES: C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)S(=O)(=O)O)C(=O)[O-])C[N+]4=CC=C(C=C4)C(=O)N
• InChI: 1S/C22H20N4O8S2/c23-18(27)13-6-8-25(9-7-13)10-14-11-35-21-15(20(29)26(21)16(14)22(30)31)24-19(28)17(36(32,33)34)12-4-2-1-3-5-12/h1-9,15,17,21H,10-11H2,(H4-,23,24,27,28,30,31,32,33,34)/t15-,17-,21-/m1/s1
• InChIKey: SYLKGLMBLAAGSC-QLVMHMETSA-N
• PubChem CID: 656575
• ChEBI ID: CHEBI:3507
• TTD Drug ID: D0XQ0Q

Type(s) of Resistant Mechanism of This Drug

  DISM: Drug Inactivation by Structure Modification

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-01: Infectious/parasitic diseases

Bacterial infection [ICD-11: 1A00-1C4Z]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Drug Inactivation by Structure Modification (DISM)

Key Molecule: 16S rRNA adenine dimethyltransferase (KsgA) [2]

• Resistant Disease: Lactobacillus casei infection [ICD-11: 1A00-1C4Z]
• Molecule Alteration: Missense mutation; A1518/1519
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: Pseudomonas aeruginosa; 1763
• Experiment for Molecule Alteration: PCR; Southern blot assay
• Experiment for Drug Resistance: MIC assay
• Mechanism Description: SOD enzymatic activity and SodM protein levels are reduced in the ksgA mutant strain;The absence of ksgA contributes to an altered antibiotic response

References

• Ref 1: Cefsulodin .Drug Intell Clin Pharm. 1986 Nov;20(11):845-9. doi: 10.1177/106002808602001104. 10.1177/106002808602001104
• Ref 2: 16S rRNA methyltransferase KsgA contributes to oxidative stress and antibiotic resistance in Pseudomonas aeruginosa. Sci Rep. 2024 Nov 3;14(1):26484.